beta-acetyldigoxin and Liver-Diseases

beta-acetyldigoxin has been researched along with Liver-Diseases* in 1 studies

Other Studies

1 other study(ies) available for beta-acetyldigoxin and Liver-Diseases

Article	Year
Elimination of 16-acetyl-gitoxin in patients suffering from impaired liver function. International journal of clinical pharmacology, therapy, and toxicology, 1987, Volume: 25, Issue:7 In ten patients suffering from moderate to severe disturbances of liver function (hepatic cirrhosis, carcinomatous metastases of the liver) the elimination of 16-acetyl-gitoxin from plasma was measured after a single oral dose of 1.2 mg pengitoxin. In 9 of 10 patients the mean half-life amounted to 67.3 h (SD 14.2 h). In one patient with carcinomatous infiltration of the liver and concomitant cirrhosis, the half-life was prolonged to 165.3 h. The results point to an unchanged elimination of 16-acetyl-gitoxin in patients suffering from liver cirrhosis. Topics: Acetyldigoxins; Adult; Aged; Biotransformation; Digoxin; Half-Life; Humans; Liver Diseases; Middle Aged	1987

Article

Year

Elimination of 16-acetyl-gitoxin in patients suffering from impaired liver function.

International journal of clinical pharmacology, therapy, and toxicology, 1987, Volume: 25, Issue:7

In ten patients suffering from moderate to severe disturbances of liver function (hepatic cirrhosis, carcinomatous metastases of the liver) the elimination of 16-acetyl-gitoxin from plasma was measured after a single oral dose of 1.2 mg pengitoxin. In 9 of 10 patients the mean half-life amounted to 67.3 h (SD 14.2 h). In one patient with carcinomatous infiltration of the liver and concomitant cirrhosis, the half-life was prolonged to 165.3 h. The results point to an unchanged elimination of 16-acetyl-gitoxin in patients suffering from liver cirrhosis.

Topics: Acetyldigoxins; Adult; Aged; Biotransformation; Digoxin; Half-Life; Humans; Liver Diseases; Middle Aged

1987